Cerevance to Participate in Piper Sandler Virtual CNS Symposium

Cerevance to Participate in Piper Sandler Virtual CNS Symposium

What's a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

‍Boston - August 7, 2025 - Cerevance, a clinical-stage biopharmaceutical company advancing multiple cell type-specific therapies for the treatment of neurodegenerative diseases and obesity, today announced participation at the Piper Sandler Virtual CNS Symposium being held from August 14-15, 2025.

Details of the event are as follows:

Q&A Session with Cerevance

• Cerevance Presenters: Craig Thompson, Chief Executive Officer and Rob Middlebrook, Chief Financial Officer
• Date/Time: Thursday, August 14, 2025, 2:30 -2:55 p.m. ET
• Location: Virtual

###‍

About Cerevance

Cerevance is focused on advancing cell type-specific therapies for the treatment of neurodegenerative and central nervous system-controlled metabolic disorders. Our proprietary platform, Nuclear Enriched Transcript Sort sequencing (NETSseq), allows us to identify targets that are expressed at very low levels, that are present in rare cell types, or that change over time as a disease progresses. Our most advanced investigational treatment, solengepras, is currently in Phase 3 development and has the potential to be a first-in-class, oral non-dopaminergic therapy for both motor and non-motor symptoms of Parkinson's disease. Our second investigational therapy, CVN766, is designed to be a highly selective oral antagonist of the orexin 1 receptor for the potential treatment of binge eating disorder and schizophrenia. Our third investigational treatment, CVN293, is a highly selective investigational oral inhibitor targeting potassium two pore domain channel subfamily K member 13 (KCNK13). CVN293 represents a potentially novel intervention point for neurodegenerative disorders and obesity.

For more information, please visit www.cerevance.com and follow us on LinkedIn and X.

Contacts

Cerevance:

Johnna Simoes, [email protected]

Media

April Dovorany, [email protected], +1-262-909-8739